Firms

Monograph Capital

Monograph Capital

monograph.bio

Monograph Capital is a transatlantic life sciences investment firm founded in 2021, with offices in London and San Francisco. It funds and helps build companies developing therapeutics, diagnostics, advanced biological manufacturing, digitally enabled healthcare and AI software for the life sciences industry. Its portfolio includes neurodegenerative gene therapy developer AviadoBio, depression therapeutics developer Autobahn Therapeutics, neuro-immunology company Sudo Biosciences, and AI platforms ODAIA and RegASK. Its team combines biomedical research, clinical medicine, investment and company-building experience. The UK advisory entity is Monograph Capital Advisors (UK) LLP, an appointed representative of FCA-regulated Odin Capital Management Ltd.

Founded
—
Type
Venture capital

Funds0

No funds on record yet.

Team

Operations and support

Brandi O’DonnellBrandi O’DonnellChief of Staff & EA
Charles ConnCharles ConnPartner
Charlie ZhouCharlie ZhouAdvisor (in Portfolio)
Daniel SchwarzDaniel SchwarzChief Financial Officer
Fred CohenFred CohenPartner and Chairman
Freddie DearFreddie DearPrincipal (Portfolio)
Jaideep DudaniJaideep DudaniPrincipal (Portfolio)
Jennifer ShahJennifer ShahHead of Capital Formation
Jeremias ReichJeremias ReichAssociate
Kristina NebelKristina NebelUS Operations Manager
Matt McAvineyMatt McAvineyPartner
Melisa GuvenMelisa GuvenPrincipal
Michelle HeMichelle HeAssociate
Mike LaGattaMike LaGattaPartner and COO
Oscar MolinaOscar MolinaAssociate
Ramone KerseyRamone KerseyUK Head of Operations
Tim FunnellTim FunnellPartner

Co-investing

LifeArc Ventures
ARCH Venture Partners
BGF
Bristol Myers Squibb
British Patient Capital

Investments

$72M2025-03-17Maxion TherapeuticsGeneral Catalyst, LifeArc Ventures, Monograph Capital, BGF, Solasta Ventures, British Patient Capital
$100M2024-07-23AutobahnARCH Venture Partners, Canaan Partners, Insight Partners, Newpath Partners, Bristol Myers Squibb, Monograph Capital
$100M2024-07-23Autobahn TherapeuticsARCH Venture Partners, Canaan Partners, Insight Partners, Newpath Partners, Bristol Myers Squibb, Monograph Capital
$147M2023-12-20Sudo BiosciencesEnavate Sciences, TPG, Sanofi Ventures, Surveyor Capital, Monograph Capital, Eventide Asset Management, Frazier Life Sciences, Dementia Discovery Fund, Leaps by Bayer, UPMC Enterprises
$80M2021-12-02AviadoBioNew Enterprise Associates, Monograph Capital, Advent Life Sciences, Dementia Discovery Fund, F-Prime Capital, LifeArc Ventures, EQT Life Sciences, Johnson & Johnson Innovation – JJDC
$72MUnknown dateMaxionGeneral Catalyst, LifeArc Ventures, Monograph Capital, BGF, Solasta Ventures, British Patient Capital